EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

The fundamentals of fibroblast growth factor 9

Hao Yin, Sabrina C R Staples, J Geoffrey Pickering

Differentiation · 2024-09 · 139 · 100731

DOI: 10.1016/j.diff.2023.09.004 ↗

At a glance

Übersichtsarbeit in Differentiation, 2024-09. Written by Hao Yin and 2 co-authors. Institution: Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Canada. Major MEDLINE topics: Fibroblast Growth Factor 9. Cited 9 times so far (Crossref); 109 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Sciences and Engineering Research Council of Canada, Schulich School of Medicine and Dentistry, Western University, Canadian Institutes of Health Research.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Fibroblast growth factor 9 (FGF9) was first identified during a screen for factors acting on cells of the central nervous system (CNS). Research over the subsequent two decades has revealed this protein to be a critically important and elegantly regulated growth factor. A hallmark control feature is reciprocal compartmentalization, particularly during development, with epithelium as a dominant source and mesenchyme a prime target. This mesenchyme selectivity is accomplished by the high affinity of FGF9 to the IIIc isoforms of FGFR1, 2, and 3. FGF9 is expressed widely in the embryo, including the developing heart and lungs, and more selectively in the adult, including the CNS and kidneys. Global Fgf9-null mice die shortly after birth due to respiratory failure from hypoplastic lungs. As well, their hearts are dilated and poorly vascularized, the skeleton is small, the intestine is shortened, and male-to-female sex reversal can be found. Conditional Fgf9-null mice have revealed CNS phenotypes, including ataxia and epilepsy. In humans, FGF9 variants have been found to underlie multiple synostoses syndrome 3, a syndrome characterized by multiple joint fusions. Aberrant FGF9 signaling has also been implicated in differences of sex development and cancer, whereas vascular stabilizing effects of FGF9 could benefit chronic diseases. This primer reviews the attributes of this vital growth factor.

Subjects

MeSH terms (MEDLINE)

Fibroblast Growth Factor 9AnimalsHumansSignal TransductionMiceCentral Nervous System

Author keywords

Fibroblast growth factor 9HeartLungMesenchymeSex reversalSynostoses syndrome

Substances

Fibroblast Growth Factor 9

Authors and institutions

  • Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Canada.
  • Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Canada; Department of Medical Biophysics, Western University, London, Canada.
  • Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Canada; Department of Medical Biophysics, Western University, London, Canada; Department of Biochemistry, Western Univer…

Funding

  • Natural Sciences and Engineering Research Council of Canada
  • Schulich School of Medicine and Dentistry, Western University
  • Canadian Institutes of Health Research

Cite

APA

Yin, H., Staples, S. C. R., & Pickering, J. G. (2024). The fundamentals of fibroblast growth factor 9. Differentiation, 139, 100731. https://doi.org/10.1016/j.diff.2023.09.004

Vancouver

Yin H, Staples SCR, Pickering JG. The fundamentals of fibroblast growth factor 9. Differentiation. 2024;139:100731. doi:10.1016/j.diff.2023.09.004

BibTeX
@article{Yin2024,
  author = {Yin, Hao and Staples, Sabrina C R and Pickering, J Geoffrey},
  title = {The fundamentals of fibroblast growth factor 9},
  journal = {Differentiation},
  year = {2024},
  volume = {139},
  pages = {100731},
  doi = {10.1016/j.diff.2023.09.004}
}
Start for free →